hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 16:36:29 - browse：2765

Joe Biden in 2016. -- first opinion coverage from STAT — President Joe Biden Elise Amendola/AP

WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few questions on how Congress might move forward with the program.

Since its launch in 2016, the federally funded cancer moonshot program has spurred thousands of scientific publications, 49 clinical trials, and more than 30 patent filings, according to a new report from the Congressional Research Service, the nonpartisan research arm of Congress.

The next phase of the cancer moonshot, according to Biden and his administration, is meant to emphasize cancer screening, prevention, and equitable treatment. The updated plan also seeks to speed progress on treatments for rare and childhood cancers, and it calls for supporting patients, survivors, and caregivers. The Advanced Research Projects Agency for Health (ARPA-H), a new agency tasked with taking big risks on biomedical and health technology, is also committing $240 million to cancer-related research and investing in new data-sharing platforms and a nationwide network for clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： How generative AI ratchets up security threats for health systems

focus

WSS

Why you shouldn’t ask, “What country has the best health care?”

Medicare drug price negotiation legal challenge met with skepticism

Zyn nicotine pouches become unlikely player in latest culture war

CVS Caremark has created a new ploy: the drug ‘rebate credit’

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

CVS Caremark has created a new ploy: the drug ‘rebate credit’

knowledge

hotspot

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Cancer drug shortages should be causing more outrage

Health AI adoption puts security, privacy startups on investors' radar

Trump demands the U.S. pay no more for drugs than other countries … again

FTC sues over Novant Health acquisition of two N.C. hospitals

Cancer drug shortages should be causing more outrage

U.K. researchers warn about biases in medical devices, algorithms

In age of alternative facts, a scholarly course on calling out crap

Biogen walks away from Aduhelm, years after polarizing approval

explore

Vertex non

Investment in vaccine development is lagging, report finds

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Zyn nicotine pouches become unlikely player in latest culture war

SCOTUS questions limit to govt efforts to fight misinformation

Why you shouldn’t ask, “What country has the best health care?”

focus

Wikipedia

focus

entertainment